Ironwood Pharmaceuticals, Inc. (IRWD), a biotechnology company, Friday provided its outlook for fiscal 2026 and confirmed its outlook for fiscal 2025.
The company expects total revenue in the range of $450 million to $475 million and Adjusted EBITDA to be greater than $300 million for the fiscal 2026.
For fiscal 2025, the Ironwood continues to expect total revenue in the range of $290 million to $310 million and Adjusted EBITDA to be greater than $135 million.
"As we close 2025, we are on track to achieve the low-end of our full-year LINZESS U.S. net sales and total revenue guidance ranges and ended the fourth quarter with greater than $200 million in cash and cash equivalents. Also, in the fourth quarter we met with the FDA to align on a confirmatory Phase 3 trial design of apraglutide for the treatment of short bowel syndrome with intestinal failure (SBS-IF). Based on this meeting, we are on track to initiate a confirmatory trial in the first half of 2026 and expect to provide details on the trial design in our fourth quarter and full-year 2025 update later this quarter.", said Tom McCourt, chief executive officer of Ironwood.
In pre-market activity, IRWD shares were trading at $4.32, up 28.78% on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.